As Sanofi declares strong early sales for Beyfortus in its second RSV season, the French pharma is confident that it would still come out on top against potential competitor Merck because ...
READ MOREValneva is eyeing a 2027 launch for its Pfizer-partnered Lyme disease vaccine, CEO Thomas Lingelbach said Thursday during the company’s investor day.
READ MOREGSK is presenting its case for broader use of its RSV vaccine with new data from a pair of studies in younger adults with underlying medical conditions and who are immunocompromised.
READ MOREGSK said it is making its largest manufacturing investment in the US yet, allocating $800 million to upgrade its vaccine production site in Pennsylvania.
READ MORE